Aptahem (APTA) Q3 2024 earnings summary

Executive summary

• Revenue for Q3 2024 was 361 KSEK, down from 1,071 KSEK year-over-year; net loss after financial items improved to -1,181 KSEK from -1,591 KSEK.

• For the nine months, revenue was 1,414 KSEK (down from 2,110 KSEK), and net loss after financial items improved to -5,688 KSEK from -6,844 KSEK year-over-year.

• Cash and cash equivalents at September 30, 2024, were 1,173 KSEK, compared to 2,914 KSEK a year earlier.

• Patent protection for Apta-1 was granted in Israel; a scientific manuscript was accepted in the British Journal of Pharmacology.

• A strategic partnership was signed with e-Projection in Japan to accelerate pharma and biotech collaborations.

Financial highlights

• Q3 operating income: 361 KSEK (1,071 KSEK in Q3 2023); nine months: 1,414 KSEK (2,110 KSEK in 2023).

• Net loss after financial items Q3: -1,181 KSEK (-1,591 KSEK in Q3 2023); nine months: -5,688 KSEK (-6,844 KSEK in 2023).

• Cash and cash equivalents at period end: 1,173 KSEK (2,914 KSEK in 2023).

• Equity ratio at period end: 95.85% (95.86% in 2023).

• Development costs for Q3 (excluding personnel): 268 KSEK (899 KSEK in Q3 2023).

Outlook and guidance

• Planning for a confirmatory phase 2 clinical study in acute inflammatory disease is underway, supported by phase 1 efficacy indications.

• Capital raised in the rights issue will fund continued clinical development and phase 2 study planning.